Trial Profile

A Phase 1b/2a, Randomized, Double-Blind, Active Controlled Study to Assess the Preliminary Clinical Efficacy, Safety, Tolerability, and Pharmacokinetics, of CYB004 in Participants With Generalized Anxiety Disorder (GAD) With Depressive Symptoms

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Apr 2024 Planned End Date changed from 14 Dec 2024 to 1 Feb 2025.
03 Apr 2024 Planned primary completion date changed from 20 Sep 2024 to 1 Nov 2024.
03 Apr 2024 Planned initiation date changed from 1 Mar 2024 to 1 May 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com